Santoro A, Musumeci R, Rilke F, Franchi F, Valagussa P, Bajetta E, Monfardini S
Tumori. 1979 Feb 28;65(1):39-49. doi: 10.1177/030089167906500105.
Sixty-one consecutive patients with chronic lymphocytic leukemia (CLL) treated at the Istituto Nazionale Tumori of Milan from September 1962 to August 1976 were classified according to the staging system of Rai et al. (16). Analysis of this series showed the following median survival (in months) from diagnosis: stage 0-I, 73; stage II, 44; stage III-IV, 32. In 11 patients without peripheral palpable adenopathies, the lymphangiogram showed abnormal retroperitoneal lymph nodes. Therefore, the initial stage was changed from 0 to I in 5 cases. The median survival for the entire series was 50 months. Patients with "indolent" disease had a median survival of 52 months, while in patients with "active" CLL, the median survival was 32 months. Both sex and age were shown to be poor predictors of survival. Increased duration of survival was observed in patients with less compared to those with more than 30,000 lymphocytes/mm3 (66 versus 41 months). The method of staging proposed by Rai et al. and utilized to classify this series at the time of diagnosis was confirmed to be a reliable predictor for survival.
1962年9月至1976年8月期间，在米兰国立肿瘤研究所接受治疗的61例连续性慢性淋巴细胞白血病（CLL）患者，根据Rai等人（16）的分期系统进行了分类。对该系列病例的分析显示，自诊断起的中位生存期（以月计）如下：0 - I期，73个月；II期，44个月；III - IV期，32个月。在11例无外周可触及淋巴结肿大的患者中，淋巴管造影显示腹膜后淋巴结异常。因此，5例患者的初始分期从0期改为I期。整个系列病例的中位生存期为50个月。“惰性”疾病患者的中位生存期为52个月，而“活动性”CLL患者的中位生存期为32个月。性别和年龄均显示出对生存期的预测能力较差。淋巴细胞计数低于30,000/mm³的患者与高于30,000/mm³的患者相比，生存期延长（分别为66个月和41个月）。Rai等人提出并在诊断时用于对该系列病例进行分类的分期方法，被证实是生存期的可靠预测指标。
